Last update: 13 August 2026 · 6-minute read
GLP-1 medicines have changed what weight loss looks like. You will know them by their brand names — Ozempic, Wegovy, Mounjaro, Zepbound. They work, and for many people they work where nothing else did.
What they cannot do is decide what kind of body the weight loss leaves behind. That part is still determined by how you eat and how you move. This guide covers what the evidence says about protecting muscle, bone and cardiorespiratory fitness while you are on one — and how little training that actually takes.
What a GLP-1 actually does
GLP-1 is a hormone your gut releases after a meal. Among other things, it tells your brain you have had enough. These medicines are engineered copies of it: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) keep that signal switched on for far longer than the natural hormone does.
The result is a substantial, sustained reduction in appetite. Calorie intake falls, and weight follows. The mechanism is not willpower and it is not metabolism — it is appetite.
Why weight loss takes lean tissue with it
Losing weight by any route means losing some lean tissue alongside fat: muscle, and bone with it. That is what an energy deficit does, and it is not a flaw specific to these medicines.
What makes it worth your attention here is scale. GLP-1s produce far greater weight loss than diet alone typically achieves, so the absolute amount of lean tissue lost is correspondingly larger. That has shifted the conversation in obesity and cardiology research away from total weight loss and towards what a 2026 European Heart Journal review calls high-quality weight loss — weight loss that preserves or improves muscle mass rather than simply lowering the number on the scale (Khan et al., 2026).
Bone deserves the same care. A 2026 review in Pharmaceuticals treats skeletal health as a distinct dimension of weight-loss quality, since pharmacologically driven energy restriction can reduce bone mineral density unless protein intake and mechanical loading are adequate (Sancho-Haro et al., 2026).
Lean mass lost is not the same as strength lost
It is easy to read “lean mass decline” as “you are getting weaker”, and the evidence does not straightforwardly support that.
A 2026 review in the British Journal of Pharmacology found that short-to-mid-term trials of semaglutide and liraglutide showed handgrip strength broadly preserved despite measurable reductions in lean soft tissue — so lean mass is not a reliable predictor of strength change. The same review flags a genuine concern at the other end: longer-term data in older adults with type 2 diabetes point to reductions in grip strength and accelerated sarcopenia with prolonged use (Prokopidis, 2026).
The honest summary is that the picture is still forming, and that age matters. If you are older, or already had low muscle mass before starting, the case for training is stronger — not weaker.
CAROL Bike is scientifically proven to reduce your risk of type 2 diabetes by 62% - and blood pressure by 5%.
What actually protects muscle
The countermeasure is well established and unglamorous: resistance training and adequate protein. Both the European Heart Journal and Pharmaceuticals reviews converge on resistance training as the primary exercise strategy for preserving skeletal muscle and physical function during pharmacological weight loss, with optimised protein intake alongside it.
A randomised controlled trial now running at the Dasman Diabetes Institute is testing exactly this combination — 232 adults starting semaglutide or tirzepatide, randomised to resistance exercise, protein at 1.6 g/kg/day, both, or neither, with MRI-measured quadriceps cross-sectional area as the primary outcome (Alawadhi et al., 2026). Its protocol is home-based: three sessions a week covering the major muscle groups. That is a reasonable template to work from while the results are pending.
A bike does not replace this. Cycling loads the lower body and will help there, but protecting muscle across the whole body needs resistance work.
The number almost nobody is watching
Muscle dominates the conversation about GLP-1s and exercise. Cardiorespiratory fitness barely features — and that is the gap worth closing.
VO₂max, or maximal oxygen uptake, is the maximum amount of oxygen your body can use during intense exercise. It is one of the strongest known predictors of all-cause mortality, ahead of blood pressure, cholesterol and BMI, and it underpins stamina and independence in later life. Genetics and age set part of it, but the main thing that moves it is vigorous activity.
Which is precisely what appears to fall. At ENDO 2026, researchers reported wearable data from 753 adults with obesity in the NIH All of Us programme, comparing activity before and after starting a GLP-1. Daily steps fell from 5,047 to 4,487 — a drop of 11%. Moderate-to-vigorous activity fell from 28 minutes a day to 22, a drop of 20%. Movement went down, not up. As the lead author put it: “while many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise.”
Two caveats belong with that finding. It was presented at a conference and has not yet been peer-reviewed, and it compared people before and after treatment without a control group — so it describes a pattern rather than proving a cause. Even so, it is the largest look we have at what happens to real-world movement on these medicines.
The consequence is quiet. You can lose weight and lose cardiorespiratory fitness at the same time, and neither the mirror nor the scale will tell you. If you want to know where you currently stand, our guide to VO₂max by age sets out what a good score looks like for your age and sex.
How little cardio is enough?
The standard advice — several 45-minute sessions a week in a hard-to-sustain heart-rate zone — asks for more than many people on a GLP-1 have to give. Appetite is down by design, and energy can feel lower with it.
Which is the argument for a much smaller dose, done properly. In the original trial of REHIT (Reduced Exertion High-Intensity Interval Training), 15 healthy but sedentary young adults completed three 10-minute cycling sessions a week for six weeks — mostly gentle pedalling, with one or two all-out sprints that built from 10 seconds in week one to 20 seconds by the final three weeks. VO₂max rose 15% in the men and 12% in the women, and insulin sensitivity rose 28% in the men, with no significant change in the women. Average perceived exertion was 13 out of 20, or “somewhat hard” (Metcalfe et al., 2012).
Across the whole six weeks that adds up to under ten minutes of genuinely hard effort — fewer than two minutes a week. Later work by the same group argues that research into sprint interval training should move towards protocols with fewer and shorter sprints, precisely because they remove the usual barriers to starting (Vollaard & Metcalfe, 2017). If you want the distinction between the protocols, we cover it in HIIT vs SIT vs REHIT.
Two things we should say plainly. That was a small trial in young, healthy volunteers. And REHIT has not been tested specifically in people taking GLP-1 medicines. What we can say is that it is the most time-efficient protocol we know of for raising VO₂max, and that time-efficiency is exactly the constraint this group is working against.
Which job does what
| What you want to protect | What does it | Realistic weekly dose |
|---|---|---|
| Muscle mass and strength | Resistance training + adequate protein | 3 sessions, major muscle groups |
| Bone density | Weight-bearing and resistance loading | Included in the above |
| Cardiorespiratory fitness (VO₂max) | Brief, genuinely hard intervals | 3 × 5-minute REHIT rides |
Working out on a GLP-1: practical adjustments
The side effects that get in the way are mostly gastrointestinal and mostly early. A few adjustments help:
- Train away from your injection day if nausea peaks predictably for you. Most people find a rhythm within a few weeks.
- Eat something small beforehand. Reduced appetite makes it easy to arrive genuinely under-fuelled, which makes hard efforts feel harder than they are.
- Drink more than feels necessary. Lower food intake means less water from food, and dehydration will flatten a session.
- Spend your appetite on protein first. If you can only eat so much, prioritise it over volume.
- Rebuild gradually after a dose increase. Side effects tend to spike, then settle.
The bottom line
The medicine handles the weight. Your job is everything else: resistance training and protein to protect muscle and bone, and a small, repeatable dose of high-intensity cardio to protect the fitness marker that predicts how well you age.
If you track anything alongside your weight, track two things — a strength number you can repeat, and a fitness number. Weight alone cannot tell you whether this is going well.
This article is general information about exercise and fitness, not medical advice. CAROL is not affiliated with any medication or its manufacturer. Speak to your healthcare provider before changing your exercise routine or your medication.
